SecBot SecBot

ACTU

ACTUATE THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001652935 Biotech & Drug Discovery
$0.4750 −0.04 (−7.95%)
Oct 23 4:00 PM ET · prev $0.5160
Market cap
$12.4M
Nano cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
🔒 Subscribers only
1 year
−93.4%
from $7.20 · Oct 24
30 days
−23.4%
from $0.6200
52-week range
$0.4340–7.63
−94% from high · low Oct 14
Avg volume 20D
398.8K
shares / day
Short interest
1.33M
≈5.5% of shares · +21.2%
Days to cover
5.6
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 4 bearish · 0 bullish oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 13, 2026
Strongest BEARISH Actuate Therapeutics filed Pre-Effective Amendment No. 2 to its S-1 registration statement for a public…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 7 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better.

  • Short sellersBUILDING

    Short interest +21.2% to 1.33M shares. 5.6 days to cover, ≈5.5% of shares.

  • TrendDOWNTREND

    51% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM112,554$172.2K
BlackRock, Inc.NEAR_EXIT90,035$137.8K
GOLDMAN SACHS GROUP INCDOUBLED35,498$54.3K
STATE STREET CORPTRIM21,850$33.4K
NORTHERN TRUST CORPNEAR_EXIT21,220$32.5K
NORTHWESTERN MUTUAL WEALTH MANAGEMENT COTRIM18,518$28.3K
DEUTSCHE BANK AG\TRIM12,235$18.7K
JPMORGAN CHASE & COADD7,626$12.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 18, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 30, 2026Rodman & Renshaw
INITIATE
INITIATEBuy
May 18, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 14, 2026
SCHMITT DANIEL M
President, CEO and Director
TAX W/H$121.7K
Aug 14, 2026
SCHMITT DANIEL M
President, CEO and Director
EXERCISE272,056 sh
May 21, 2026
Huber Martin H. Jr.
Director
AWARD15,000 sh
May 21, 2026
Fletcher Aaron G.L.
Director
AWARD15,000 sh
May 21, 2026
Keyes Jason A
Director
AWARD15,000 sh
May 21, 2026
RONNEBERG AMY L
Director
AWARD15,000 sh
May 21, 2026
Sawhney Roger
Director
AWARD15,000 sh
May 21, 2026
THOMSON TODD S
Director
AWARD15,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
1,330,078
shares short
+21.2%
vs prior settlement
5.6
days to cover
≈5.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Actuate Therapeutics filed Pre-Effective Amendment No. 2 to its S-1 registration statement for a public offering of…
S-1/A — Impact 7/10
Oct 14, 2026 SEC
Actuate Therapeutics filed Pre-Effective Amendment No. 1 to its S-1 registration statement for a follow-on offering of…
S-1/A — Impact 6/10
Oct 6, 2026 SEC
Actuate Therapeutics, a clinical-stage biopharmaceutical company developing elraglusib (a GSK-3 inhibitor for…
S-1 — Impact 7/10
Sep 30, 2026 Short interest report
Short Interest: ACTU up 21% to 1.3M shares
Settlement 2026-09-30 | Days to cover: 5.61 | ≈5.54% of shares outstanding (est.)
Aug 14, 2026 Insider
SCHMITT DANIEL M surrendered for taxes 120,521 shares
President, CEO and Director @ $1.01 ($121.7K)
Aug 14, 2026 Insider
SCHMITT DANIEL M acquired via exercise 272,056 shares
President, CEO and Director
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
112,554 shares ($172.2K)
Jun 30, 2026 Inst.
BlackRock, Inc. — NEAR_EXIT
90,035 shares ($137.8K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 13, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Sep 30, 2026
Short interest
Short Interest: ACTU up 21% to 1.3M shares
Settlement 2026-09-30 | Days to cover: 5.61 | ≈5.54% of shares outstanding (est.)
Sep 9, 2026
Press release
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a…
Sep 9, 2026
Contract
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a…
Aug 31, 2026
Short interest
Short Interest: ACTU up 69% to 1.2M shares
Settlement 2026-08-31 | Days to cover: 1.92 | ≈4.88% of shares outstanding (est.)
Aug 14, 2026
Earnings date
ACTU Q2 2026 Earnings Scheduled — 2026-08-14

SecBot reports

7 filings · 3 press releases · 0 bullish · 4 bearish · 1 mixed · 2 neutral
All ACTU filing & press-release reports (10)